Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 1 of 18 PageID #: 997
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`GENENTECH, INC. and CITY OF HOPE,
`
`Plaintiffs and Counterclaim Defendants,
`
`v.
`
`PFIZER INC.,
`
`Defendant and Counterclaim Plaintiff.
`
`
`
`
`GENENTECH, INC., CITY OF HOPE, and
`HOFFMANN LA ROCHE INC.,
`
`Plaintiffs and Counter Defendants,
`
`v.
`
`CELLTRION, INC., CELLTRION,
`HEALTHCARE CO., LTD., TEVA
`PHARMACEUTICALS USA, INC., and
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH,
`
`Defendants and Counterclaim Plaintiffs.
`
`
`
`
`GENENTECH, INC. and CITY OF HOPE,
`
`Plaintiffs and Counterclaim Defendants,
`
`v.
`
`
`AMGEN, INC.,
`
`Defendant and Counterclaim Plaintiff.
`
`
`
`
`
`
`ME1 28420102v.1
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`C.A. No. 17-1672-CFC
`
`C.A. No. 18-95-CFC
`
`
`
`C.A. No. 18-924-CFC
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 2 of 18 PageID #: 998
`
`GENENTECH, INC., CITY OF HOPE, and
`HOFFMANN LA ROCHE INC.,
`
`Plaintiffs and Counter Defendants,
`
`v.
`
`CELLTRION, INC., CELLTRION,
`HEALTHCARE CO., LTD., TEVA
`PHARMACEUTICALS USA, INC., and
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH,
`
`Defendants and Counterclaim Plaintiffs.
`
`
`
`
`
`GENENTECH, INC. and CITY OF HOPE,
`
`Plaintiffs,
`
`v.
`
`SAMSUNG BIOEPIS CO., LTD,
`
`Defendant.
`
`
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`C.A. No. 18-1025-CFC
`
`
`C.A. No. 18-1363-CFC
`
`SCHEDULING ORDER
`
`This ___ day of _________, 2018, the Court having conducted a scheduling conference
`
`pursuant to Local Rule 16.1(b), and the parties having determined after discussion that the matter
`
`cannot be resolved at this juncture by settlement, voluntary mediation, or binding arbitration:
`
`IT IS ORDERED that:
`
`1.
`
`Rule 26(a)(1) Initial Disclosures and E-Discovery Default Standard. All parties
`
`except those in Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd.¸ C.A. No. 18-1363-CFC have
`
`exchanged Rule 26(a)(1) Initial Disclosures, and the parties in the Samsung action shall
`
`exchange them within 5 days of the date of this Order. If they have not already done so, the
`
`ME1 28420102v.1
`
`2
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 3 of 18 PageID #: 999
`
`parties in each of the above-captioned cases are to meet and confer on a Proposed Standard for
`
`Discovery of Electronically Stored Information (“Proposed ESI Order”). Such Proposed ESI
`
`Orders shall be filed no later than November 16, 2018.
`
`2.
`
`Joinder of Other Parties and Amendment of Pleadings. All motions to join other
`
`parties, and to amend or supplement the pleadings, shall be filed on or before April 5, 2019.
`
`3.
`
`Discovery.
`
`a.
`
`Discovery Cut Off. All discovery in this case shall be initiated so that it
`
`will be completed on or before May 13, 2019. The Plaintiffs and Defendant Groups1 will
`
`provide final contentions no later than the close of fact discovery.
`
`b.
`
`Document Production. Substantial completion of document production
`
`shall be completed on or before January 14, 2019.
`
`c.
`
`Discovery Limits. The parties are conferring to discuss limits on
`
`coordinated discovery, including depositions and written discovery. The parties will report back
`
`to the court at a later date with a joint proposal for such discovery limits, or, to the extent the
`
`parties are unable to submit a joint proposal, competing proposals that conform to the Court’s
`
`procedures for disputes relating to discovery matters. The parties further agree and stipulate that
`
`depositions shall not proceed until either the parties reach agreement or an order from the Court
`
`issues regarding appropriate limitations for depositions.
`
`
`1
`“Defendant Group” shall be defined to include all parties sued by Plaintiffs in a
`single cause of action. The four Defendant Groups are: (1) Pfizer Inc.; (2) Celltrion, Inc.,
`Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc., and Teva
`Pharmaceuticals International GMBH; (3) Amgen, Inc.; and (4) Samsung Bioepis Co.,
`Ltd.
`
`
`ME1 28420102v.1
`
`3
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 4 of 18 PageID #: 1000
`
`4.
`
`Application to Court for Protective Order. A protective order has been entered in
`
`Genentech, Inc. et al. v. Pfizer Inc., C.A. No. 17-1672-CFC. The parties in Genentech, Inc. et al.
`
`v. Celltrion, Inc. et al., C.A. No. 18-95-CFC, Genentech, Inc. et al. v. Amgen, Inc.¸ C.A. No. 18-
`
`924-CFC, and Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd.¸ C.A. No. 18-1363-CFC, will
`
`propose protective orders for the Court’s entry within two weeks from the date of this Order, and
`
`such proposed orders will include the following paragraph:
`
`Other Proceedings. By entering this order and limiting the
`disclosure of information in this case, the Court does not intend to
`preclude another court from finding that information may be
`relevant and subject to disclosure in another case. Any person or
`party subject to this order who becomes subject to a motion to
`disclose another party’s information designated as confidential
`pursuant to this order shall promptly notify that party of the motion
`so that the party may have an opportunity to appear and be heard
`on whether that information should be disclosed.
`
`5.
`
`Disputes Relating to Discovery Matters and Protective Orders. Should counsel
`
`find they are unable to resolve a dispute relating to a discovery matter or protective order, the
`
`parties shall contact the Court’s Case Manager to schedule an in-person conference/argument.
`
`Unless otherwise ordered, by no later than 48 hours prior to the conference/argument, the party
`
`seeking relief shall file with the Court a letter, not to exceed three pages, outlining the issues in
`
`dispute and the party’s position on those issues. The party shall submit as attachments to its letter
`
`(1) an averment of counsel that the parties made a reasonable effort to resolve the dispute and
`
`that such effort included oral communication that involved Delaware counsel for the parties, and
`
`(2) a draft order for the Court’s signature which identifies with specificity the relief sought by the
`
`party. By no later than 24 hours prior to the conference/argument, any party opposing the
`
`application for relief may file a letter, not to exceed three pages, outlining that party’s reasons for
`
`its opposition. Should any document(s) be filed under seal, a courtesy copy of the sealed
`
`ME1 28420102v.1
`
`4
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 5 of 18 PageID #: 1001
`
`document(s) must be provided to the Court within one hour of e-filing the document(s). If a
`
`motion concerning a discovery matter or protective order is filed without leave of the Court, it
`
`will be denied without prejudice to the moving party’s right to bring the dispute to the Court
`
`through the procedures set forth in this paragraph.
`
`6.
`
`Papers Filed Under Seal. When filing papers under seal, counsel shall deliver to
`
`the Clerk an original and one copy of the papers. A redacted version of any sealed document
`
`shall be filed electronically within seven days of the filing of the sealed document.
`
`7.
`
`Courtesy Copies. The parties shall provide to the Court two courtesy copies of all
`
`briefs and one courtesy copy of any other document filed in support of any briefs (i.e.,
`
`appendices, exhibits, declarations, affidavits etc.). This provision also applies to papers filed
`
`under seal.
`
`8.
`
`Claim Construction Issue Identification. Subject to Plaintiffs’ reservation of due
`
`process rights stated on the record at the October 16, 2018 status conference, on or before
`
`November 7, 2018, Plaintiffs shall narrow the number of patents and claims asserted in this
`
`litigation against each Defendant Group to ten (10) patents with a maximum of two (2) claims
`
`per patent. Of the ten (10) patents per Defendant Group, at least six (6) patents must be the same
`
`for all Defendant Groups, with no more than 30 claims in total from these six (6) patents
`
`identified across the Defendant Groups. Absent further Order of the Court on a motion by
`
`Plaintiffs based on constitutional due process notions, no other patents or claims will be asserted
`
`against any Defendant Group in this litigation beyond those identified on or before November 7,
`
`2018 in accordance with this Paragraph. For avoidance of doubt, nothing in this Paragraph shall
`
`preclude Plaintiffs from seeking leave to assert additional patents or claims based upon changed
`
`circumstances—such as, for example, material changes to a Defendant’s product or
`
`ME1 28420102v.1
`
`5
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 6 of 18 PageID #: 1002
`
`manufacturing process, or the issuance of a new patent. On or before November 14, 2018, the
`
`parties shall exchange a list of those claim term(s)/phrase(s) that they believe need construction.
`
`On or before November 20, 2018, the parties shall exchange their proposed claim constructions
`
`of those term(s)/phrase(s). The list of claim term(s)/phase(s) and proposed constructions will not
`
`be filed with the Court. Subsequent to exchanging these lists, the parties will meet and confer no
`
`later than November 28, 2018 to prepare a Joint Claim Construction Chart to be filed no later
`
`than December 5, 2018. The Joint Claim Construction Chart, in Word format, shall be e-mailed
`
`simultaneously with filing to cfc_civil@ded.uscourts.gov. The text for the Joint Claim
`
`Construction Chart shall be 14-point and in a Times New Roman or similar typeface. The
`
`parties’ Joint Claim Construction Chart should identify for the Court the term(s)/phrase(s) of the
`
`claim(s) in issue and should include each party’s proposed construction of the disputed claim
`
`language with citation(s) only to the intrinsic evidence in support of their respective proposed
`
`constructions. A copy of the patent(s) in issue as well as those portions of the intrinsic record
`
`relied upon shall be submitted with this Joint Claim Construction Chart. In this joint submission,
`
`the parties shall not provide argument.
`
`9.
`
`Claim Construction Briefing. The Plaintiffs shall serve, but not file, its opening
`
`brief, not to exceed 5,500 words, on January 11, 2019. The Defendants shall serve, but not file,
`
`their answering brief, not to exceed 8,250 words for arguments common to all Defendants, with
`
`an additional 1,250 words per Defendant Group to make separate arguments, on February 15,
`
`2019. The Plaintiffs shall serve, but not file, their reply brief, not to exceed 5,500 words plus
`
`1,250 words for each Defendant Group that made separate arguments, on March 6, 2019. The
`
`Defendants shall serve, but not file, their sur-reply brief, not to exceed 2,750 words for
`
`arguments common to all Defendants, with an additional 500 words per Defendant Group to
`
`ME1 28420102v.1
`
`6
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 7 of 18 PageID #: 1003
`
`make separate arguments, on March 20, 2019. The text for each brief shall be 14-point and in a
`
`Times New Roman or similar typeface. Each brief must include a certification by counsel that
`
`the brief complies with the type and number limitations set forth above. The person who prepares
`
`the certification may rely on the word count of the word-processing system used to prepare the
`
`brief.
`
`No later than March 22, 2019, the parties shall file a Joint Claim Construction Brief. The
`
`parties shall copy and paste their untitled briefs into one brief, with their positions on each claim
`
`term in sequential order, in substantially the form below.
`
`JOINT CLAIM CONSTRUCTION BRIEF
`
`I.
`
`II.
`
`A.
`
`1.
`2.
`3.
`4.
`
`Agreed-upon Constructions
`
`Disputed Constructions
`
`[TERM 1]
`
`Plaintiffs’ Opening Position
`Defendants’ Answering Position
`Plaintiffs’ Reply Position
`Defendants’ Sur-Reply Position
`
`B.
`
`[TERM 2]
`
`Plaintiffs’ Opening Position
`Defendants’ Answering Position
`Plaintiffs’ Reply Position
`Defendants’ Sur-Reply Position
`
`1.
`2.
`3.
`4.
`
`Etc. The parties need not include any general summaries of the law relating to claim
`
`construction. If there are any materials that would be submitted in an appendix, the parties shall
`
`submit them in a Joint Appendix.
`
`10.
`
`Hearing on Claim Construction. Beginning at 9:00 a.m. on April 24, 2019, the
`
`Court will hear argument on claim construction. The Court has reserved a full day for such
`
`argument. Absent prior approval of the Court (which, if it is sought, must be done so by joint
`
`ME1 28420102v.1
`
`7
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 8 of 18 PageID #: 1004
`
`letter submission no later than the date on which answering claim construction briefs are due to
`
`be served), the parties shall not present testimony at the argument.
`
`11.
`
`Disclosure of Expert Testimony.
`
`a.
`
`Expert Reports. For the party who has the initial burden of proof on the
`
`subject matter the initial Federal Rule 26(a)(2) disclosure of expert testimony is due on or before
`
`June 28, 2019. The supplemental disclosure to contradict or rebut evidence on the same matter
`
`identified by another party, including Plaintiffs’ positions regarding secondary considerations of
`
`non-obviousness, is due on or before August 9, 2019. Reply expert reports from Defendants,
`
`limited to contradicting or rebutting Plaintiffs’ positions on secondary considerations of non-
`
`obviousness, are by August 23, 2019. No other expert reports will be permitted without either
`
`the consent of all parties or leave of the Court. Along with the submissions of the expert reports,
`
`the parties shall advise of the dates and times of their experts’ availability for deposition.
`
`Depositions of experts shall be completed on or before September 27, 2019.
`
`12.
`
`Applications by Motion. Except as otherwise specified herein, any application to
`
`the Court shall be by written motion. Any non-dispositive motion should contain the statement
`
`required by Local Rule 7.1.1.
`
`13.
`
`Pretrial Conference. On November __, 2019, the Court will hold a Rule 16(e)
`
`final pretrial conference in Court with counsel beginning at [TIME] _.m. The parties shall file a
`
`joint proposed final pretrial order in compliance with Local Rule 16.3(c) no later than 5:00 p.m.
`
`on the third business day before the date of the final pretrial conference. Unless otherwise
`
`ordered by the Court, the parties shall comply with the timeframes set forth in Local Rule 16.3(d)
`
`for the preparation of the proposed joint final pretrial order.
`
`ME1 28420102v.1
`
`8
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 9 of 18 PageID #: 1005
`
`14. Motions in Limine. Motions in limine shall not be separately filed. All in limine
`
`requests and responses thereto shall be set forth in the proposed pretrial order. Each party shall
`
`be limited to three in limine requests, unless otherwise permitted by the Court. The in limine
`
`request and any response shall contain the authorities relied upon; each in limine request may be
`
`supported by a maximum of three pages of argument and may be opposed by a maximum of
`
`three pages of argument, and the party making the in limine request may add a maximum of one
`
`additional page in reply in support of its request. If more than one party is supporting or
`
`opposing an in limine request, such support or opposition shall be combined in a single three-
`
`page submission (and, if the moving party, a single one-page reply). No separate briefing shall be
`
`submitted on in limine requests, unless otherwise permitted by the Court.
`
`15.
`
`Compendium of Cases. A party may submit with any briefing two courtesy copies
`
`of a compendium of the selected authorities on which the party would like the Court to focus.
`
`The parties should not include in the compendium authorities for general principles or
`
`uncontested points of law (e.g., the standards for summary judgment or claim construction). An
`
`authority that is cited only once by a party generally should not be included in the compendium.
`
`An authority already provided to the Court by another party should not be included in the
`
`compendium.
`
`16.
`
`Trial. These matters should be trial ready in anticipation of a nine (9)-day bench
`
`trial beginning at 9:30 a.m. on December 9, 2019, with the subsequent trial days beginning at
`
`9:30 a.m. The issues and parties included in this trial will be determined at a future point in the
`
`pre-trial process. The trial will be timed, as counsel will be allocated a total number of hours in
`
`which to present their respective cases.
`
`ME1 28420102v.1
`
`9
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 10 of 18 PageID #: 1006
`
`17.
`
`ADR Process. This matter is referred to a magistrate judge to explore the
`
`possibility of alternative dispute resolution.
`
`18.
`
`Prior Scheduling Order. The dates outlined above supersede those dates
`
`previously entered in the September 17, 2018 Scheduling Order.
`
`19.
`
`Summary of Case Schedule.
`
`#
`
`Event
`
`Proposed Date
`
`1. Deadline for initial disclosures in Genentech, Inc. et
`al. v. Samsung Bioepis Co., Ltd.¸ C.A. No. 18-1363-
`CFC
`
`Five (5) days of the date of
`this Order
`
`2. Deadline to submit proposed protective orders to the
`Court
`
`Two (2) weeks from the date
`of this Order
`
`3. Deadline for Plaintiffs to identify for each Defendant
`Group ten (10) patents, with a maximum of two (2)
`claims per patent
`
`November 7, 2018
`
`4. Deadline for parties to submit Proposed ESI Orders
`to the Court
`
`November 16, 2018
`
`5. Deadline for parties to exchange a list of those claim
`term(s)/phrase(s) that they believe need construction
`
`November 14, 2018
`
`6. Deadline for the parties to exchange their proposed
`claim constructions of those term(s)/phrase(s)
`
`November 20, 2018
`
`7. Deadline for parties to meet-and-confer on claim
`construction
`
`November 28, 2018
`
`8. Deadline for parties to submit Joint Claim
`Construction Chart
`
`December 5, 2018
`
`ME1 28420102v.1
`
`10
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 11 of 18 PageID #: 1007
`
`#
`
`Event
`
`Proposed Date
`
`9. Deadline for Plaintiff to serve opening claim
`construction brief
`
`January 11, 2019
`
`10. Deadline for substantial completion of document
`production
`
`January 14, 2019
`
`11. Deadline for Defendants to serve answering claim
`construction brief
`
`February 15, 2019
`
`12. Deadline for Plaintiff to serve reply claim
`construction brief
`
`March 6, 2019
`
`13. Deadline for Defendants to serve sur-reply claim
`construction brief
`
`March 20, 2019
`
`14. Deadline for parties to file a Joint Claim
`Construction Brief
`
`March 22, 2019
`
`15. Deadline for joinder of other parties and amendment
`of pleadings
`
`April 5, 2019
`
`16. Claim construction hearing (full day)
`
`April 24, 2019 at 9:00 a.m.
`
`17. Fact-discovery cut-off
`
`May 13, 2019
`
`18. Deadline to provide final contentions
`
`May 13, 2019
`
`19. Deadline for disclosure of expert testimony for the
`party who has the initial burden of proof on the
`subject matter
`
`June 28, 2019
`
`20. Deadline for disclosure to contradict or rebut expert
`evidence identified by another party, including
`Plaintiffs’ positions regarding secondary
`
`August 9, 2019
`
`ME1 28420102v.1
`
`11
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 12 of 18 PageID #: 1008
`
`#
`
`Event
`
`Proposed Date
`
`considerations of non-obviouesnss
`
`21. Deadline for Defendants’ reply expert reports,
`limited to contradicting or rebutting Plaintiffs’
`positions on secondary considerations of non-
`obviousness
`
`August 23, 2019
`
`22. Expert discovery cut-off
`
`September 27, 2019
`
`23. Pretrial conference
`
`November __, 2019 at ____
`
`24. Trial (9 days)
`
`December 9, 2019 at 9:30 a.m.
`
`Respectfully submitted,
`
`
`
`
`
`ME1 28420102v.1
`
`12
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 13 of 18 PageID #: 1009
`
`
`
`
`
`
`
`
`
`/s/ Dominick T. Gattuso
`
`Dominick T. Gattuso (#3630)
`HEYMAN ENERIO GATTUSO & HIRZEL LLP
`300 Delaware Ave. Suite 200
`Wilmington, DE 19801
`(308) 472-7300
`dgattuso@hegh.law
`
`OF COUNSEL:
`Thomas J. Meloro
`Michael W. Johnson
`Diana Santos
`Dan Constantinescu
`WILLKIE FARR & GALLAGHER LLP
`787 Seventh Avenue
`New York, NY 10019
`(212) 728-8000
`
`Attorneys for Defendant and Counterclaim
`Plaintiff
`
`
`Case 17-1672-CFC
`
`/s/ Frederick L. Cottrell, III
`Frederick L. Cottrell, III (#2555)
`Jason J. Rawnsley (#5379)
`RICHARDS, LAYTON & FINGER, P.A.
`920 North King Street
`Wilmington, DE 19801
`(302) 651-7700
`cottrell@rlf.com
`rawnsley@rlf.com
`
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Kevin S. Prussia
`Andrew J. Danford
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, MA 02109
`(627) 526-6000
`
`Robert J. Gunther Jr.
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`(212) 230-8800
`
`Robert Galvin
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`950 Page Mill Road
`Palo Alto, CA 94304
`(650) 858-6000
`
`Daralyn J. Durie
`Adam R. Brausa
`DURIE TANGRI LLP
`217 Leidesdorff St.
`San Francisco, CA 94111
`(415) 362-6666
`
`Attorneys for Plaintiffs and Counterclaim
`Defendants
`
`
`
`
`
`ME1 28420102v.1
`
`13
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 14 of 18 PageID #: 1010
`
`Cases 18-95-CFC and 18-1025-CFC
`
`
`
`
`/s/ Karen E. Keller
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`
`Kevin DeJong
`Molly Grammel
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`(617) 570-1000
`kdejong@goodwinlaw.com
`mgrammel@goodwinlaw.com
`
`Elizabeth J. Holland
`Robert V. Cerwinski
`Cynthia Lambert Hardman
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`eholland@goodwinlaw.com
`mgrammel@goodwinlaw.com
`
`
`Attorneys for Defendants and Counterclaim
`Plaintiffs Celltrion, Inc., Celltrion
`Healthcare, Co. Ltd., Teva Pharmaceuticals
`USA, Inc., and Teva Pharmaceuticals
`International GmbH
`
`
`
`
`
`
`
`/s/ Jack B. Blumenfeld
`Jack B. Blumenfeld (#1014)
`Karen Jacobs (#2881)
`Morris, Nichols, Arsht & Tunnell LLP
`1201 North Market Street, 16th Floor
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`kjacobs@mnat.com
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Kevin S. Prussia
`Andrew J. Danford
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, MA 02109
`(627) 526-6000
`william.lee@wilmerhale.com
`lisa.pirozzolo@wilmerhale.com
`emily.whelan@wilmerhale.com
`kevin.prussia@wilmerhale.com
`andrew.danford@wilmerhale.com
`
`Robert J. Gunther Jr.
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`(212) 230-8800
`robert.gunther@wilmerhale.com
`
`Robert Galvin
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`950 Page Mill Road
`Palo Alto, CA 94304
`(650) 858-6000
`robert.galvin@wilmerhale.com
`
`
`
`ME1 28420102v.1
`
`14
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 15 of 18 PageID #: 1011
`
`Daralyn J. Durie
`Adam R. Brausa
`DURIE TANGRI LLP
`217 Leidesdorff St.
`San Francisco, CA 94111
`(415) 362-6666
`ddurie@durietangri.com
`abrausa@durietangri.com
`
`Attorneys for Plaintiffs and Counterclaim
`Defendants
`Genentech, Inc., City of Hope, and Hoffman-
`La Roche Inc.
`
`
`
`
`
`
`ME1 28420102v.1
`
`15
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 16 of 18 PageID #: 1012
`
`
`
`Case 18-924-CFC
`
`
`
`
`
`
`/s/ Daniel M. Silver
`Michael P. Kelly (#2295)
`Daniel M. Silver (#4758)
`MCCARTER &ENGLISH, LLP
`Renaissance Centre
`405 North King Street, 8th Floor
`Wilmington, DE 19801
`(302) 984-6300
`mkelly@mccarter.com
`dsilver@mccarter.com
`
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Kevin S. Prussia
`Andrew J. Danford
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, MA 02109
`(627) 526-6000
`william.lee@wilmerhale.com
`lisa.pirozzolo@wilmerhale.com
`emily.whelan@wilmerhale.com
`kevin.prussia@wilmerhale.com
`andrew.danford@wilmerhale.com
`
`Robert J. Gunther Jr.
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`(212) 230-8800
`robert.gunther@wilmerhale.com
`
`Daralyn J. Durie
`Adam R. Brausa
`DURIE TANGRI LLP
`217 Leidesdorff St.
`San Francisco, CA 94111
`(415) 362-6666
`ddurie@durietangri.com
`
`
`/s/ Eve H. Ormerod
`Neal C. Belgam (No. 2721)
`Eve H. Ormerod (No. 5369)
`SMITH KATZENSTEIN & JENKINS LLP
`1000 West Street, Suite 1501
`Wilmington, DE 19801
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`
`OF COUNSEL:
`
`Michelle Rhyu
`Susan Krumplitsch
`Daniel Knauss
`COOLEY, LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`P 650-843-5287
`skrumplitsch@cooley.com
`mrhyu@cooley.com
`dknauss@cooley.com
`
`Orion Armon
`COOLEY, LLP
`380 Interlocken Crescent, Suite 900
`Broomfield, CO 80021-8023
`(720) 566-4119
`oarmon@cooley.com
`
`Eamonn Gardner
`COOLEY, LLP
`4401 Eastgate Mall
`San Diego, CA 92121-1909
`(858) 550-6086
`egardner@cooley.com
`
`Nancy Gettel
`Thomas Lavery, IV
`AMGEN, INC.
`One Amgen Center Drive
`Thousand Oaks, CA 91320-1799
`P 805-447-1000
`
`ME1 28420102v.1
`
`16
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 17 of 18 PageID #: 1013
`
`abrausa@durietangri.com
`
`Attorneys for Plaintiffs
`Genentech, Inc. and City of Hope
`
`
`
`
`
`
`ngettel@amgen.com
`tlavery@amgen.com
`
`Attorneys for Defendant Amgen, Inc.
`
`ME1 28420102v.1
`
`17
`
`

`

`Case 1:18-cv-01363-CFC Document 25 Filed 10/24/18 Page 18 of 18 PageID #: 1014
`
`
`
`
`
`Case 18-1363-CFC
`
`
`/s/ Frederick L. Cottrell, III
`Frederick L. Cottrell, III (#2555)
`Jason J. Rawnsley (#5379)
`RICHARDS, LAYTON & FINGER, P.A.
`920 North King Street
`Wilmington, DE 19801
`(302) 651-7700
`cottrell@rlf.com
`rawnsley@rlf.com
`
`Attorneys for Plaintiffs
`
`
`
`/s/ David E. Moore
`
`David E. Moore (#3983)
`Bindu Palapura (#5370)
`POTTER ANDERSON & CORROON LLP
`Hercules Plaza, 6th Floor
`1313 North Market Street
`P.O. Box 951
`Wilmington, DE 19801
`(302) 984-6000
`dmoore@potteranderson.com
`bpalapura@potteranderson.com
`
`OF COUNSEL:
`
`Dimitrios T. Drivas
`Scott T. Weingaertner
`Amit H. Thakore
`Holly Tao
`WHITE & CASE LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Tel: (212) 819-8200
`
`Attorneys for Defendant Samsung Bioepis
`Co., Ltd.
`
`
`
`
`
`
`
`
`
`ME1 28420102v.1
`
`18
`
`